PYC Therapeutics shares gained 5.1% as investors looked ahead to clinical data for PYC-003, an experimental RNA treatment for inherited polycystic kidney disease. Biotechnology stocks are known for sharp price swings around clinical results, and PYC's shares could move significantly in either direction once the kidney data is released. ... Lakefront Biotherapeutics Shares Jump 7.36% as Former Galapagos NV Continues Its Ongoing Corporate Reinvention · Viking Therapeutics Shares Soar 30% as Obesity Drug Trial Shows 97% Weight Loss Retention on Reduced Dosing PYC is also developing VP-001 for retinitis pigmentosa type 11, an inherited condition that causes progressive blindness, and PYC-002 for Phelan-McDermid syndrome, a rare neurodevelopmental disorder. The company focuses on monogenic diseases, which are caused by a mutation in a single gene. PYC has said such conditions have a higher likelihood of success in clinical development than the industry average. PYC remains a clinical-stage company and is not yet profitable. For the 2026 fiscal year, it reported revenue of about 26 million Australian dollars and a net loss of about 43.3 million Australian dollars, a smaller loss than the previous year. Registrational trials in kidney disease are typically long and costly, because they need to show effects on kidney function or accepted surrogate measures over an extended period. PYC Therapeutics Shares Jump 5% as Investors Bet on Kidney Disease Data From RNA Drug Developer This Year · SYDNEY — Shares of PYC Therapeutics rose more than 5% on Tuesday, extending a strong run for the Perth-based RNA drug developer as investors position ahead of a key data readout for its experimental treatment for an inherited kidney disease.

Original title: “PYC Therapeutics Shares Jump 5% as Investors Bet on Kidney Disease Data From RNA Drug Developer This Year”